ClinicalTrials.gg
TerminatedNCT03978611Updated Jul 24, 2024

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

A Phase 1 interventional study of Relatlimab and Ipilimumab in Melanoma, sponsored by Bristol-Myers Squibb. Terminated at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives have changed.

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing relatlimab in Melanoma — 6 open to participants now, 10 under way, 1 of them phase 3. relatlimab · Melanoma.

Enrollment
14th of 16
11 · median 48
Started
2021
with 1 other
Phase 1
2 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
5 of 16
Bristol-Myers Squibb

Among the 16 studies testing relatlimab in Melanoma, this one is the 14th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 5th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 16 studies testing relatlimab in Melanoma are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About relatlimab

relatlimab: first FDA approval 2022 (OPDUALAG), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing relatlimab in Melanoma, or all of them as a file.
02

Study summary

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have documented progression while on a prior anti-programmed cell death protein 1 () containing regimen limited to Nivolumab or Pembrolizumab
  • Must have confirmed advanced unresectable (Stage III) or (Stage IV) melanoma, as per (AJCC) staging system
  • Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses
  • (ECOG) 0-1

Exclusion criteria

Exclusion Criteria:

  • History of uveal melanoma
  • Known history of positive test for (HIV) or known acquired immunodeficiency syndrome
  • Prior treatment with ipilimumab, relatlimab, or any other cytotoxic T-lymphocyte-associated antigen 4 () or lymphocyte-activation gene 3 (LAG-3) targeted agents
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation Phase

    Drug: Relatlimab · Drug: Ipilimumab

Interventions

  • Specified dose on specified days

    Also known as: BMS-986016

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Up to Follow-up Period (100 days after 34 cycles [1 cycle is of 3 weeks])

  2. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to Follow-up Period (100 days after 34 cycles [1 cycle is of 3 weeks])

  3. Number of Participants With Adverse Events Including Dose Limiting Toxicity

    Time frame: Up to 28 days after last study drug dose (approximately up to 2 years)

  4. Number of Participants with AEs resulting in Discontinuation

    Time frame: Up to end of study (approximately 2.4 years)

  5. Number of Participants with AEs resulting in Death

    Time frame: Up to end of study (approximately 2.4 years)

  6. Number of Participants with AEs resulting in Laboratory Abnormalities

    Time frame: Up to end of study (approximately 2.4 years)

07

Study locations

28 sites
  • Local Institution - 0023
    Tucson, Arizona 85724, United States
  • Local Institution - 0002
    Los Angeles, California 90033, United States
  • Local Institution - 0005
    Los Angeles, California 90033, United States
  • Local Institution - 0001
    Santa Monica, California 90404, United States
  • Local Institution - 0015
    Miami, Florida 33136, United States
  • Local Institution - 0004
    Chicago, Illinois 60611, United States
  • Local Institution - 0003
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0008
    Morristown, New Jersey 07960, United States
  • Local Institution - 0018
    Bruxelles, Brussels 1000, Belgium
  • Local Institution - 0017
    Antwerpen, 2020, Belgium
  • Local Institution - 0016
    Brussels, 1090, Belgium
  • Local Institution - 0038
    Bruxelles, 1200, Belgium
  • Local Institution - 0044
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0037
    Erlangen, 91054, Germany
  • Local Institution - 0034
    Essen, 45147, Germany
  • Local Institution - 0036
    Gera, 07548, Germany
  • Local Institution - 0035
    Hannover, 30625, Germany
  • Local Institution - 0033
    Heidelberg, 69120, Germany
  • Local Institution - 0032
    Lübeck, 23562, Germany
  • Local Institution - 0040
    Nuremberg, 90419, Germany
  • Local Institution - 0053
    Padova, 35128, Italy
  • Local Institution - 0055
    Siena, 53100, Italy
  • Local Institution - 0026
    Barcelona, 08035, Spain
  • Local Institution - 0030
    Cordoba, 14004, Spain
  • Local Institution - 0027
    Hospitalet de Llobregat - Barcelona, 08908, Spain
  • Local Institution - 0029
    Madrid, 28034, Spain
  • Local Institution - 0031
    San Sebastian, 20014, Spain
  • Local Institution - 0028
    Valencia, 46009, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jul 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jun 7, 2019
StartActual
Dec 9, 2021
Primary completionActual
Jul 26, 2023
CompletionActual
Jul 26, 2023
Last update
Jul 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03978611
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Dec 9, 2021
Primary completion
Jul 26, 2023
Completion
Jul 26, 2023
Last update
Jul 24, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relatlimab

Start the discussion